The prevalence of acute erosive-ulcerative gastroduodenal lesions in patients with cardiovascular diseases, taking anticoagulants and antiplatelet agents
A. A. Poliantsev,
D. V. Frolov,
D. V. Linchenko,
S. N. Karpenko,
A. A. Chernovolenko,
Yu. A. Dyachkova https://doi.org/10.31146/1682-8658-ecg-169-9-65-74
Abstract
Aims: to draw attention to the lack of recommendations for the prevention and treatment of acute erosive-ulcerative gastroduodenal lesions and their complications associated with the severity of the patient’s condition, the massiveness of antiplatelet and anticoagulant therapy and the degree of risk of bleeding.
Materials and methods: a literature review was conducted of domestic and foreign authors on the problem of pathogenesis, clinical manifestations, diagnosis, treatment and prevention of lesions of the upper gastrointestinal tract in cardiovascular diseases.
Results: there are no standardized recommendations for the prevention and treatment of OEGP and their complications, taking into account the individual characteristics of the patient, based on evidence.
Conclusion: it is necessary to develop a scale that assesses the risk of OEGP and gastrointestinal bleeding in cardiovascular diseases, methods of treatment and prevention of these conditions, taking into account the specific parameters of the patient.
About the Authors
A. A. Poliantsev
Volgograd State Medical University
Russian Federation
Aleksandr A. Poliantsev, Doctor of Medicine, Professor, Head Department of General Surgery with urology, 400131, Volgograd, Russia
Russian Federation
Aleksandr A. Poliantsev, Doctor of Medicine, Professor, Head Department of General Surgery with urology, 400131, Volgograd, Russia
D. V. Frolov
Volgograd State Medical University
Russian Federation
Denis V. Frolov, MD, associate professor of the department of general surgery with urology, cardiovascular surgeon, 400131, Volgograd, Russia
Russian Federation
Denis V. Frolov, MD, associate professor of the department of general surgery with urology, cardiovascular surgeon, 400131, Volgograd, Russia
D. V. Linchenko
Volgograd State Medical University
Russian Federation
Diana V. Linchenko, Ph.D., associate professor of the Department of General Surgery with urology, 400131, Volgograd, Russia
Russian Federation
Diana V. Linchenko, Ph.D., associate professor of the Department of General Surgery with urology, 400131, Volgograd, Russia
S. N. Karpenko
Volgograd State Medical University
Russian Federation
Svetlana N. Karpenko, Ph.D., assistant of the Department of General Surgery with urology, 400131, Volgograd, Russia
Russian Federation
Svetlana N. Karpenko, Ph.D., assistant of the Department of General Surgery with urology, 400131, Volgograd, Russia
A. A. Chernovolenko
Volgograd State Medical University
Russian Federation
Andrej A. Chernovolenko, assistant of the Department of General Surgery with urology, 400131, Volgograd, Russia
Russian Federation
Andrej A. Chernovolenko, assistant of the Department of General Surgery with urology, 400131, Volgograd, Russia
Yu. A. Dyachkova
Volgograd State Medical University
Russian Federation
Yulija A. Dyachkova, 5th year student of the Faculty of Medicine, 400131, Volgograd, Russia
Russian Federation
Yulija A. Dyachkova, 5th year student of the Faculty of Medicine, 400131, Volgograd, Russia
References
1. WHO Available at: http://www.whogis.com/ru/ (accessed 17 May 2017)
2. Vertkin AL, Zajrat’ janc OV, Vovk EI. Porazhenie zheludka i dvenadcatiperstnoj kishki u bol’nyh s ostrym koronarnym sindromom. Lechashhij vrach. 2005; 1:66–70.
3. Vertkin AL, Zajrat’ janc OV, Vovk EI. Okonchatel’nyj diagnoz. Moscow: GJeOTAR-Media; 2008.
4. Kolobov SV, Zajrat’ janc OV, Poputchikova EA. Morfologicheskie osobennosti ostryh jerozij i jazv zheludka u bol’nyh infarktom miokarda pri lechenii preparatom «Losek». Morfologicheskie vedomosti. 2002; 3(4): 80–82.
5. Kolobov SV, Zajrat’ janc OV, Hohlova EE, Frolova Ju V. Ostrye jerozivno-jazvennye porazhenija zheludka pri neotlozhnyh sostojanijah u bol’nyh terapevticheskogo profilja. In: Proceedings of the VI Congress of the Scientific Society of Gastroenterologists of Russia. Moscow; 2006. P. 24–25.
6. Kolobov SV, Vertkin AL, Zajrat’ janc OV et al. Ostrye jerozivno-jazvennye porazhenija verhnih otdelov zheludochno-kishechnogo trakta u bol’nyh infarktom miokarda. In: Proceedings of the II Congress of the Russian Society of Pathologists. Moscow; 2006. P. 70–71.
7. Kolobov SV, Zajrat’ janc OV, Vovk EI et al. Ostrye jerozivno-jazvennye porazhenija verhnih otdelov zheludochno-kishechnogo trakta. In: Proceedings “Actual issues of morphogenesis in health and disease”. Moscow: NII morfologii cheloveka RAMN; 2006. P. 17–18.
8. Kolobov SV, Zajrat’ janc OV, Hohlova EE. Jerozivnojazvennye porazhenija zheludka i dvenadcatiperstnoj kishki i zheludochno-kishechnye krovotechenija u bol’nyh infarktom miokarda. In: Proceedings of the VII Moscow Assembly “Capital Health”. M; 2008. P. 305–306.
9. Mayev IV. Erosive gastritis: discrete nosological itemor universal response of mucosa to damage? Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2005:15(6): 53–59.
10. Hohlova EE, Kolobov SV, Zajrat’ janc OV, Zajrat’ janc GO. Ostrye jerozivno-jazvennye gastroduodenal’nye porazhenija i krovotechenija u bol’nyh terapevticheskogo i nevrologicheskogo profilja. In: Proceedings of the III Congress of the Russian Society of Pathologists. Samara: SamGMU; 2009. P. 325
11. Yarema IV, Kolobov SV, Zajrat’yants OV et al. Acute erosive ulcer gastro-duodenal defeats at patients with ischemic heart disease, cerebrovascular illness and chronic obstructive pulmonary disease. Hirurg. 2009; 12: 5–13.
12. Ivashkin VT, Sheptulin AA. Jerozivno-jazvennye porazhenija zheludka i dvenadcatiperstnoj kishki, obuslovlennye nesteroidnymi protivovospalitel’nymi preparatami. Vrach. 2001; 3: 22–23.
13. Zajrat’ janc OV, Kolobov SV, Hohlova EE, Poputchikova EA Ostrye jerozivno-jazvennye gastroduodenal’nye porazhenija u terapevticheskih i nevrologicheskih bol’nyh. In: Proceedings of the conference of the memory of Yu. L. Perov. Moscow: Izd-vo MGU; 2009. P. 35–43.
14. Zajrat’ janc OV, Kolobov SV., Poljanko NI, Hohlova EE. Ostrye jerozivno-jazvennye krovotechenija u bol’nyh terapevticheskogo i nevrologicheskogo profilja. In: Proceedings of the VIII Moscow Assembly “Capital Health”. M; 2009. P. 256–257.
15. Kolobov SV, Zajrat’ janc OV, Loranskaja ID et al. Jerozivno-jazvennye porazhenija verhnih otdelov zheludochno-kishechnogo trakta u bol’nyh ostrym infarktom miokarda. Neotlozhnaja terapija. 2002; 3(4): 63–67.
16. Kolobov SV, Zajrat’ janc OV, Loranskaja ID et al. Jerozivno-jazvennye porazhenija zheludka i dvenadcatiperstnoj kishki pri ostrom infarkte miokarda. Eksp Klin Gastroenterol. 2003;1: 95–97.
17. Kolobov SV, Vertkin AL, Zajrat’ janc OV et al. Lechenie i profilaktika zheludochno-kishechnyh krovotechenij u bol’nyh s obostreniem IBS. Terapevt. 2006; 6: 15–28
18. Mihajlov AP, Danilov AM, Napalkov AN, Shul’gin VL. Ostrye jazvy i jerozii pishhevaritel’nogo trakta: Uchebnoe posobie. St. Petersburg: Izd-vo S.-Peterb. Un-ta; 2004.
19. Gel’fand B.R., Gur’janov V.A., Martynov A. N., et al. Profilaktika stress-povrezhdenij zheludochno-kishechnogo trakta u bol’nyh v kriticheskih sostojanijah. Consilium Medicum. 2005; 7(6): 464–467.
20. Stocko JuM, Kurygin AA, Musinov IM. Vagotomija v lechenii ostryh izjazvlenij zheludka, oslozhnennyh tjazhelym krovotecheniem. Vestnik hirurgii. 2001; 3: 25–29.
21. Chernov VN, Miziev IA, Belik BM. Prognozirovanie i profilaktika vozniknovenija ostryh jazv i jerozij zheludka i dvenadcatiperstnoj kishki u hirurgicheskih bol’nyh. Vestnik hirurgii. 1999; 6: 12–15.
22. Sheptulin AA. Gastropatija, svjazannaja s priemom nesteroidnyh protivovospalitel’nyh preparatov: faktory riska, lechenie, profilaktika. Klin. perspektivy v gastrojenterologii i gepatologii. 2001; 1: 27–31.
23. ESC-2017: obnovljonnye klinicheskie rekomendacii. Diagnostika i lechenie zabolevanij perifericheskih arterij. Sovremennaja kardiologija. 2017; 3(05): 3.
24. Kalinin AV. Simptomaticheskie gastroduodenal’nye jazvy i jazvennaja bolezn’. Ros. zhurn. gastrojenterol, gepatol., koloproktol. 2004; 3: 22–31.
25. Sulejmanov Z, Gidajatov A, Karaev G et al. Lokalizacija aktivnyh ionov vodoroda v slizistoj obolochke zheludka. Klinicheskaja medicina. 2006; 9: 66–68.
26. Sachs G., Prinz, C. K. Hersey, S. J. Mechanism of acid secretion. Acidrelated disorders.Palm Beach, Fla.: Sushu Publishing Inc.;1995. – № 2. – P. 63.
27. Sokolova GN, Tsaregorodsteva TM, Tkachenko EV, Serova TI. Immune mechanism in patho and sanogenesis of stomach ulcer of aged patients. Klinicheskaja gerontologija. 2006; 12(1): 34–40.
28. Leontiadis G. I., Sharma V. K., Howden C. W. Proton pump inhibitor treatment f or acute peptic ulcer bleeding. Cochrane Database Syst Rev, 2006, V.25, № 1, P. CD002094. https://doi.org/10.1002/14651858.cd002094.pub3
29. Triadafilopoulos G. Review article: the role of antisecretory therapy in management of non-variceal upper gastrointestinal bleeding. Aliment Pharmacol Ther, 2005, V.22, № s3, P. 53–58. https://doi.org/10.1111/j.1365–2036.2005.02717.x
30. Zvenigorodskaja LA, Gorunovskaja IG. Osobennosti jazvennoj bolezni u lic pozhilogo i starcheskogo vozrasta. Klinicheskaja gerontologija. 2003; 9: 50–51.
31. Cherniaev, A. Ia. Clinical and morphological characteristics of ulcer in elderly patients. Eksp Klin Gastroenterol. 2002;(2):18–21.
32. Zvenigirodskaia LA, Kuznetsov MP, Samsonova NG, Taranchenko Iu V. Chronic ischemic disease of the digestive system. Eksp Klin Gastroenterol. 2002; 2:13–17.
33. Pimanov SI, Semenova EV, Makarenko EV, Ruselik EA. Gastroduodenal’nye jazvy, vyzyvaemye antiagregantami i nesteroidnymi protivovospalitel’nymi preparatami: profilaktika po novym rekomendacijam. Consilium medicum. 2009; 11(8):13–20.
34. Lazebnik LB, Zvenigorodskij LA Metabolicheskij sindrom i organy pishhevarenija. Moscow, Anaharsis; 2009, 184 p.
35. Osadchij V A. Sostojanie mikrocirkuljacii, simpatoadrenalovoj i gistaminoreaktivnoj sistem i vlijanie ih izmenenij na osobennosti recidiva jazvennoj bolezni u bol’nyh infarktom miokarda. Klin. med. 2005; 3: 34–38.
36. Pimanov SI, Makarenko EV. Optimized eradication protocols: recommendations of the American gastroenterologist board, Masstrikht V/Florentine and Toronto consensuses. Medicinskij sovet. 2017; 15: 10–17.
37. Maev IV, Samsonov AA. Sovremennye standarty lechenija kislotozavisimyh zabolevanij, associirovannyh s H. pylori (materialy konsensusa Maastriht-3). Consilium Medicum. Gastrojenterologija. 2006; 8(1) (Pril.): 3–8.
38. Starostin BD. Treatment of Helicobacter pylori infection – Maastricht V/Florentine consensus report (translation with commentary). Gastroenterologia St. Petersburga. 2017;1: 2–22.
39. Melnikov MV, Sabodash VB, Apresyan AY. The state of mucous membrane of the stomach and duodenum patients with obliterating atherosclerosis. Fundamental’nye issledovanija. 2013; 2: 117–120.
40. Smol’kina AV, Maksin AA, Shabaev RM, Rogova JuJu. Sochetanie zabolevanij gastroduodenal’noj zony s kriticheskoj ishemiej nizhnih konechnostej. Angiologija i sosudistaja hirurgija. 2012; 2 (Prilozh.): 363–364.
41. Fokin AA, Olevskaja ER, Orehova LA et al. Zabolevanija proksimal’nogo otdela zheludochno-kishechnogo trakta u bol’nyh s okkljuzionno-stenoticheskimi izmenenijami brjushnoj aorty i arterij nizhnih konechnostej. Angiologija i sosudistaja hirurgija. 1999; 2: 114–118.
42. Bel’kov JuA, Shinkevich JeV, Makeev AG et al. Taktika lechenija bol’nyh s hronicheskoj ishemiej nizhnih konechnostej pri jerozivno-jazvennyh gastroduodenitah. Hirurgija. 2004; 3: 38–41.
43. Braunwald E, Antman E. M., Beasley J. W. et al. ACC/ AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article: A report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation, 2002, V.106, № 14, P. 1893–1900. https://doi.org/10.1161/01.cir.0000037106.76139.53
44. Lanas A., Garcia-Rodriguez L.A., Arroyo M. T. et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut, 2006, V.55, № 12, P. 1731–1738. https://doi.org/10.1136/gut.2005.080754
45. Siller-Matula J.M., Spiel A. O., Lang I. M. et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J, 2009, V.157, № 1, P. 148.e1–148. e5. https://doi.org/10.1016/j.ahj.2008.09.017
46. Dewilde W. J.M., Oirbans T., Verheugt F. W. WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 2013, V.381, № 9872, P. 1107–1115. https://doi.org/10.1016/s0140–6736(12)62177–1
47. Gao F., Zhou Y. J., Wang Z. J. et al. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. Int. J. Cardiol, 2011, V. 148, № 1, P. 96–101.
48. Gibson C. M., Chakrabarti A. K., Mega J. et al. ATLAS ACS-2-TIMI 51 Investigators. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS2 TIMI 51. J. Am. Coll. Cardiol, 2013, V.62, № 4, P. 286–290. https://doi.org/10.1016/j.jacc.2013.03.041
49. Lamberts M., Olesen J. B., Ruwald M. H. et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohortstudy. Circulation, 2012, V.126, № 10, P. 1185–1193. https://doi.org/10.1161/circulationaha.112.114967
50. Mega J. L., Braunwald E., Wiviott S. D. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med, 2012, V.366, № 1, P. 9–19. https://doi.org/10.1056/nejmoa1112277
51. Pipilis A., Lazaros G., Tsakonas G. Triple Antithrombotic Therapy with Aspirin, a Thienopyridine Derivative Plus Oral Anticoagulation in Patients with Atrial Fibrillation Undergoing Coronary Stenting. Hellenic J. Cardiol, 2010, № 51, P. 330–337.
52. Sorensen R., Hansen M. L., Abildstrom S. Z. et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet, 2009, V.374,№ 9706, P. 1967–1974. https://doi.org/10.1016/s0140–6736(09)61751–7
53. Steg P. G., Huber K., Andreotti F. et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur. Heart J, 2011, V.32, № 15, P. 1854–1864. https://doi.org/10.1093/eurheartj/ehr204
54. Eikelboom J. W., Mehta S. R., Anand S. S. et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndrome. Circulation, 2006, V.114, № 8, P. 774–782. https://doi.org/10.1161/circulationaha.106.612812
55. Hamon M., Lemesle G., Tricot O. et al. Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease. J. Am. Coll. Cardiol, 2014, V.64, № 14, P. 1430–1436. https://doi.org/10.1016/j.jacc.2014.07.957
56. Lamberts M., Gislason G. H., Olesen J. B. et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J. Am. Coll. Cadiol. 2013, V.62, № 11, P. 981–989. https://doi.org/10.1016/j.jacc.2013.05.029
57. Moscucci M. Predictors of major bleeding in acute coronary syndromes; the Global Registry of Acute Coronary Events (GRACE). Eur. Heart J, 2003, V.24, № 20, P. 1815–1823. https://doi.org/10.1016/s0195–668x(03)00485–8
58. De Caterina R., Husted S., Wallentin L. et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes ESC Working group on thrombosis. Task Force on anticoagulants in heart disease position paper. J. Am. Coll. Cardiol, 2012, V.59, № 16, P. 1413–1425. https://doi.org/10.1016/j.jacc.2012.02.008
59. Faxon D. P., Eikelboom J. W., Berger P. et al. Consensus document: antithrombotic therapy inpatients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb. Haemost, 2011, V.106, № 10, P. 571–584. https://doi.org/10.1160/th11–04–0262
60. Heidbuchel H., Verhamme P., Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013, V.15, № 3, P. 625–651. https://doi.org/10.1093/europace/eut083
61. Heidbuchel H., Verhamme P., Alings M. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, V.17, № 10, P. 1467–1507. https://doi.org/10.1093/europace/euv309
62. Karjalainen P. P., Vikman S., Niemela M. et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur. Heart J, 2008, V.29, № 8, P. 1001–1010. https://doi.org/10.1093/eurheartj/ehn099
63. Lip G. Y., Huber K., Andreotti F. et al. Consensus Document of European Society of Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting. Eur. Heart J, 2010, V.31,№ 11, P. 1311–1318. https://doi.org/10.1093/eurheartj/ehq117
64. Lip G. Y., Windecker S., Huber K. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and AsiaPacific Heart Rhythm Society (APHRS). Eur. Heart J, 2014, V.35, № 45. – 3155– 3179. https://doi.org/10.1093/eurheartj/ehu298
65. Windecker S., Kolh P., Alfonso F. et al. Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J, 2014, V.35, № 37, P. 2541– 2619. https://doi.org/10.1093/eurheartj/ehu278
66. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016, V.37, № 38, P. 2893–2962.
67. Chan F. K.L. The David Y. Graham Lecture: Use of Nonsteroidal Antiinflammatory Drugs in a COX-2 Restricted Environment. Am J Gastroenterol, 2008, V.103, № 1, P. 221–227. https://doi.org/10.1111/j.1572–0241.2007.01545.x
68. Eniseeva ES. Double and triple antithrombotic therapy in atrial fibrillation and acute coronary syndrome. Sibirskij medicinskij zhurnal (Irkutsk). 2016; 2: 18–22.
69. Arents N. L.A., Thijs J. C., van Zwet A. A. et al. Approach to treatment of dyspepsia in primary care: a randomized trial comparing ‘test-and-treat’ with prompt endoscopy. Arch Intern Med 2003, № 163(13), P. 1606–1612. https://doi.org/10.1001/archinte.163.13.1606
70. Duggan A. E., Elliott C. A., Miller P. et al. Clinical trial: a randomized trial of early endoscopy, Helicobacter pylori testing and empirical therapy for the management of dyspepsia in primary care. Aliment Pharmacol Th er, 2009, № 29, P. 55–68. https://doi.org/10.1111/j.1365–2036.2008.03852.x
71. Lassen A. T., Pedersen F. M., Bytzer P. et al. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomized trial. Lancet. 2000, № 356, P. 455–460. https://doi.org/10.1016/s0140–6736(00)02553–8
72. McColl K.E.L., Murray L. S., Gillen D. et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H pylori testing alone in the management of dyspepsia. BMJ. – 2002, № 324, P. 999–1002. https://doi.org/10.1136/bmj.324.7344.999
73. Delaney B., Ford A. C., Forman D. et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev, 2005. – № 4, P. CD001961. https://doi.org/10.1002/14651858.cd001961.pub2
74. Moayyedi P., Eikelboom J. W., Bosch J. et al. LB15 – A randomized trial of proton pump inhibitors versus placebo to prevent upper gastrointestinal bleeding in patients receiving Rivaroxaban or Aspirin. United European Gastroenterology Ueg Week, 2018.
Review
For citations:
Poliantsev A.A., Frolov D.V., Linchenko D.V., Karpenko S.N., Chernovolenko A.A., Dyachkova Yu.A. The prevalence of acute erosive-ulcerative gastroduodenal lesions in patients with cardiovascular diseases, taking anticoagulants and antiplatelet agents. Experimental and Clinical Gastroenterology. 2019;(9):65-74. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-169-9-65-74
Views:
529
Email this article 